Prof Sandip Patel speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the DART study, which examined the administration of ipilimumab plus nivolumab to achieve dual checkpoint inhibition in a cohort of patients with rare neuroendocrine tumours.

Prof Patel reports that these patients experienced a 44 percent reduction in tumour size, compared with patients with lower, intermediate disease - who experienced a 0 percent rate of shrinkage.

Although it is unclear why patients with high-grade neuroendocrine carcinoma benefitted from this study, Prof Patel points out that it may be attributed to a mutational burden; in which specimens are being assessed to understand the underlying tumour biology.

He also believes in the next three years, oncologists will be able to determine which rare tumour types display a sensitivity to immune checkpoint blockade - which may include high-grade neuroendocrine carcinoma.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

This 15-minute presentation by Thor Halfdanarson, MD Mayo Clinic, provides a concise introduction to NET diagnosis and treatment.
0:25 What are NETs
1:25 Tumor grade and differentiation
4:10 Tumor stage
4:36 Prevalence of NETs
5:38 Signs & symptoms of NETs
6:58 Carcinoid syndrome
7:27 Hormonal symptoms
8:37 Diagnosis
10:06 Functional tumors
10:55 Treatment
12:42 SI-NETs treatment
13:22 Pan-NETs treatment
14:30 Summary

Quality of life can be just as important as survival. As GI cancer research increasingly puts a focus on the entire cancer journey, oncologists like Dr Matthew Burge are asking: are the benefits of treatment worth the cost to quality of life for patients?

At the GI Cancer Institute, we believe that every GI cancer patient has the right to live their life to the fullest. STOPNET is a trial that is seeking to find out whether some of these unpleasant treatments can be reduced without a negative effect on the patient's cancer.

01:15 When to operate
6:16 lung-sparing surgery
12:17 Wedge resection
12:23 Segmentectomy
14:10 Central tumor removal
15:45 Summary

When intestinal neuroendocrine tumors (NETs) metastasize to the liver, people can develop carcinoid syndrome, which can also occur with lung, ovarian, and other types of NETs. Dr. Lowell Anthony, Dr. Aman Chauhan, Dr. Shikha Jain, and Dr. Edward Wolin explain carcinoid syndrome and why it occurs, how it can be confused with other health conditions, its impact on quality of life, and treatment options.

This video explains what the Neuroendocrine system and neuroendocrine cells do to regulate hormones in the body. When these cells change they can develop into Neuroendocrine Tumours (NETs). We explain where they can occur in the body and why.